CeCors / PsyKey (OTC: $CEOS ) Announce Head of Glo
Post# of 58
(Total Views: 262)
Posted On: 11/05/2022 9:04:17 AM
CeCors / PsyKey (OTC: $CEOS ) Announce Head of Global Business Development
https://thestreetreports.com/cecors-psykey-ot...velopment/
CECORS, INC. (OTC: CEOS) subsidiary PsyKey Inc. an innovative wellness company, is pleased to announce the appointment of John Gustin as head of global business development. John Gustin is a veteran corporate executive and scientific innovator with more than three decades of experience building some of the fastest-growing nutritional companies.
Market Action
On Monday, CEOS stock was in action with a gain of as much as 9.79% in the intra-day session on hefty volume. The stock traded 1.45 million shares, compared to its average volume of 308K shares. The stock moved within a range of $0.0157 – 0.0269 after opening trade at $0.0221.
As it happens, the company was in fact in the news yesterday after its fully owned subsidiary company PsyKey Inc made a major new announcement.
However, before that, it may be a good move to take a look at PsyKey as a business unit. PsyKey is involved in the fast-growing innovative wellness space and is involved with the commercialization as well as the development of adaptogenic, ethnogenic, and nootropic formulations and ingredients. The company is involved in mushrooms starting from the medicinal ones to the functional ones.
In addition to that, the company is also well aware of the fact that people need to have easy access to healthcare personnel and support services. It has made significant progress on that particular front as well.
Yesterday, PsyKey announced that it had appointed a new global head of business development in the form of John Gustin. In this situation, it could be a good idea for investors to take a closer look at Gustin’s credentials and figure out if the appointment is going to be positive for PsyKey or not.
Gustin is a highly experienced executive as well as a scientific innovator who has been involved in building up some of the quickest-growing nutritional firms and brands over a period of more than thirty years.
However, it is perhaps more important to note that over the course of his career he has also been responsible for the development and patenting of a large number of formulations that have been successful in the wellness and functional health spaces. It now remains to be seen if the CECORS stock manages to get any action in the coming days or not.
Traders Note
CEOS stock is trading below the 20-Day and 50-Day Moving averages of $0.0290 and $0.0341 respectively. Moreover, the stock is trading below the 200-Day moving average of $0.0586.
https://thestreetreports.com/cecors-psykey-ot...velopment/
CECORS, INC. (OTC: CEOS) subsidiary PsyKey Inc. an innovative wellness company, is pleased to announce the appointment of John Gustin as head of global business development. John Gustin is a veteran corporate executive and scientific innovator with more than three decades of experience building some of the fastest-growing nutritional companies.
Market Action
On Monday, CEOS stock was in action with a gain of as much as 9.79% in the intra-day session on hefty volume. The stock traded 1.45 million shares, compared to its average volume of 308K shares. The stock moved within a range of $0.0157 – 0.0269 after opening trade at $0.0221.
As it happens, the company was in fact in the news yesterday after its fully owned subsidiary company PsyKey Inc made a major new announcement.
However, before that, it may be a good move to take a look at PsyKey as a business unit. PsyKey is involved in the fast-growing innovative wellness space and is involved with the commercialization as well as the development of adaptogenic, ethnogenic, and nootropic formulations and ingredients. The company is involved in mushrooms starting from the medicinal ones to the functional ones.
In addition to that, the company is also well aware of the fact that people need to have easy access to healthcare personnel and support services. It has made significant progress on that particular front as well.
Yesterday, PsyKey announced that it had appointed a new global head of business development in the form of John Gustin. In this situation, it could be a good idea for investors to take a closer look at Gustin’s credentials and figure out if the appointment is going to be positive for PsyKey or not.
Gustin is a highly experienced executive as well as a scientific innovator who has been involved in building up some of the quickest-growing nutritional firms and brands over a period of more than thirty years.
However, it is perhaps more important to note that over the course of his career he has also been responsible for the development and patenting of a large number of formulations that have been successful in the wellness and functional health spaces. It now remains to be seen if the CECORS stock manages to get any action in the coming days or not.
Traders Note
CEOS stock is trading below the 20-Day and 50-Day Moving averages of $0.0290 and $0.0341 respectively. Moreover, the stock is trading below the 200-Day moving average of $0.0586.
(0)
(0)